MAP2K5 and chronic myelogenous leukemia, BCR-ABL1 positive: In line with these observations, Tusa and colleagues demonstrated that targeting the MEK5/ERK5 pathway in chronic myeloid leukemia (CML) led to a drastic decrease in progenitor/stem cells number due to a cell cycle block in G0/G1 [125].